New Developments in Salivary Gland Pathology: Clinically Useful Ancillary Testing and New Potentially Targetable Molecular Alterations

• Published in: Archives of pathology & laboratory medicine (1976) Vol. 141; no. 3; pp. 381 - 395
• Main Authors: Griffith, Christopher C, Schmitt, Alessandra C, Little, James L, Magliocca, Kelly R
• Format: Journal Article
• Language: English
• Published: United States College of American Pathologists 01.03.2017
• Subjects: Chromosome abnormalities; Diagnosis; Genetic aspects; Health aspects; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Innovations; Molecular diagnostic techniques; Salivary Gland Neoplasms - diagnosis; Salivary gland tumors
• ISSN: 0003-9985; 1543-2165; 1543-2165
• DOI: 10.5858/arpa.2016-0259-sa

Accurate diagnosis of salivary gland tumors can be challenging because of the many diagnostic entities, the sometimes extensive morphologic overlap, and the rarity of most tumor types. Ancillary testing is beginning to ameliorate some of these challenges through access to newer immunohistochemical stains and fluorescence in situ hybridization probes, which can limit differential diagnostic considerations in some cases. These ancillary testing strategies are especially useful in small biopsy samples, including aspiration cytology. Molecular techniques are also expanding our understanding of salivary gland tumor pathology and are helping to identify potential targets that may improve treatment for some of these tumors. Here, we summarize the clinical use of new immunohistochemical markers in our practice and review the current understanding of chromosomal rearrangements in salivary gland tumor pathology, emphasizing the prospects for exploiting molecular alterations in salivary gland tumors for diagnosis and targeted therapy. We find that immunohistochemistry and fluorescence in situ hybridization are powerful tools toward the diagnosis of salivary gland tumors, especially when used in a systematic manner based on morphologic differential-diagnostic considerations. As new targeted therapies emerge, it will become increasingly vital to incorporate appropriate molecular testing into the pathologic evaluation of salivary gland cancers.